Teal Health – Weekly Recap

Teal Health is a women-led digital health company focused on innovating cervical cancer screening, and this weekly recap highlights a pivotal expansion of its at-home testing offering and its growing policy and industry role. During Cervical Cancer Awareness Month, the company advanced its mission to improve screening access and adherence by achieving nationwide availability of its FDA-authorized at-home cervical cancer screening self-collection device, the Teal Wand, and by leading a broad coalition to promote routine screening and HPV vaccination.

Teal Health has moved into full national commercialization, making its self-collection device and virtual care platform available to women in all 50 U.S. states. The service allows patients to order a kit online, complete a telehealth visit to confirm eligibility, collect an HPV sample at home using an FDA-approved test, and receive results and follow-up through a secure portal, with the ability to share information with existing healthcare providers. The company reports coverage with most major insurance plans, with a pricing model that includes insurance reimbursement, direct pay options, and partnerships with payers, health systems, employers, and provider organizations. Typical pricing is $99 for in-network insured patients and $249 for self-pay, with HSA/FSA eligibility.

Teal’s growth strategy targets the large underscreened segment of the population, as roughly one in three U.S. women are behind on cervical cancer screening. By emphasizing convenience, privacy, and avoidance of speculum-based exams, the company aims to improve adherence, a dynamic similar to the increased uptake seen in other at-home screening modalities. Clinical validation from a 16-site national trial showed that Teal Wand self-collected samples detected cervical precancer 96% of the time, comparable to clinician-collected samples, and 94% of participants preferred the at-home method.

On the policy and advocacy front, Teal is spearheading a coalition of more than 30 women’s health and lifestyle brands to normalize cervical cancer screening and HPV vaccination, positioning elimination of cervical cancer as a realistic public health goal. At the same time, updated guidelines from the American Cancer Society and the U.S. Department of Health and Human Services now recommend or endorse HPV self-collection and require insurance coverage for screening and follow-up by January 2027, providing a favorable regulatory backdrop. Teal’s leadership role in the Cervical Cancer Roundtable, a collaboration between the American Cancer Society and the federal Cancer Moonshot initiative, further embeds it in the guideline and policy ecosystem.

Taken together, national commercialization, strong clinical data, increasing insurance coverage, and alignment with evolving federal guidelines position Teal Health to capture a meaningful share of the cervical cancer screening market and to influence future standards of care, marking a notably constructive week for the company’s long-term prospects.